What is Neurocrine Biosciences's SG&A?

Neurocrine Biosciences (NBIX) reported SG&A of $318.5M in Q1 2026.

How has Neurocrine Biosciences's SG&A changed year-over-year?

Neurocrine Biosciences's SG&A increased by 15.2% year-over-year, from $276.5M to $318.5M.

What is the long-term trend for Neurocrine Biosciences's SG&A?

Over 4 years (2021 to 2025), Neurocrine Biosciences's SG&A has grown at a 18.7% compound annual growth rate (CAGR), from $583.3M to $1.16B.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Neurocrine Biosciences NBIX SG&A

SG&A at other companies

Bristol-Myers SquibbBMY

$1.62B+2.1%

Acadia PharmaceuticalsACAD

$171.02M+35.3%

CRN

CRNXCRNX

$47.83M+91.8%

BridgeBio PharmaBBIO

$163.9M+54.1%

BiogenBIIB

$607.3M+6.1%

Rhythm Pharmaceuticals, Inc.RYTM

$63.59M+62.7%

Segments

By segment

See full

Reportable Segment$318.5M+15.2%

Other financials

Income statement

See full

Revenue$814.5M+42.2%

Gross profit$800.7M+42.1%

Operating income$193.4M+719%

Net income$197.9M+2,405%

EPS (diluted)$1.91+2,287%

Balance sheet

See full

Cash & equivalents$274.5M+35.8%

Total debt$463.5M-6.0%

Total equity$3.4B+34.4%

Total assets$4.9B+33.0%

Cash flow

See full

Operating cash flow$145.8M+125%

CapEx$9.1M-15.0%

Free cash flow$136.7M+153%

Valuation

See full

Market cap$17.3B+29.6%

Enterprise value$17.49B+28.9%

P/E25.9×-12.5×

P/S5.6×+0.3×

Profitability

See full

Gross margin98.2%-0.3pp

Operating margin25.4%+4.9pp

Net margin21.6%+8.9pp

FCF margin26.8%+6.4pp

Returns & leverage

See full

Return on equity22.5%+10.1pp

Debt / equity0.1×-0.1×

Current ratio2.9×-0.2×

Where this comes from

Reported directly by Neurocrine Biosciences in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neurocrine Biosciences's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Neurocrine Biosciences's SG&A?: Neurocrine Biosciences (NBIX) reported SG&A of $318.5M in Q1 2026.
How has Neurocrine Biosciences's SG&A changed year-over-year?: Neurocrine Biosciences's SG&A increased by 15.2% year-over-year, from $276.5M to $318.5M.
What is the long-term trend for Neurocrine Biosciences's SG&A?: Over 4 years (2021 to 2025), Neurocrine Biosciences's SG&A has grown at a 18.7% compound annual growth rate (CAGR), from $583.3M to $1.16B.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.